# A Study of AZD8233 in Participants With Dyslipidemia

Study · id `cardio:ct-nct04641299` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04641299](<https://clinicaltrials.gov/study/NCT04641299>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04641299

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.

## Technical summary

Registry record NCT04641299. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-28 (actual); primary completion 2021-07-20 (actual). Results posted on 2022-11-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 119 participants (enrolled count; ClinicalTrials.gov record NCT04641299, source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)
- Started: 2020-10-28 (actual) (ClinicalTrials.gov record NCT04641299, source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)
- Primary completion: 2021-07-20 (actual) (ClinicalTrials.gov record NCT04641299, source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)
- Completion: 2021-07-20 (actual) (ClinicalTrials.gov record NCT04641299, source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)
- Results first posted: 2022-11-18 (ClinicalTrials.gov record NCT04641299, source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)
- Countries: United States; Denmark; Slovakia (ClinicalTrials.gov record NCT04641299, source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04641299-2022-11-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of AZD8233 in Participants With Dyslipidemia
- Condition: Dyslipidaemia
- Intervention (Drug): AZD8233
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 8844db0c5284c1fe73b36c22a5eab11fc088dd164952683b00f30dd17eb2bedf
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
